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Melatonin and its metabolites
protect human melanocytes
against UVB-induced damage:
Involvement of NRF2-mediated
pathways
Zorica Janjetovic1,2, Stuart G. Jarrett3, Elizabeth F. Lee2, Cory Duprey2, Russel J. Reiter4 &
Andrzej T. Slominski 1,2,5,6
Ultraviolet light (UV) is an inducer of reactive oxygen species (ROS) as well as 6-4-photoproducts
and cyclobutane pyrimidine dimers (CPD) in the skin, which further cause damage to the skin cells.
Irradiation of cultured human melanocytes with UVB stimulated ROS production, which was reduced in
cells treated with melatonin or its metabolites: 6-hydroxymelatonin (6-OHM), N1-acetyl-N2-formyl-5methoxykynuramine (AFMK), N-acetylserotonin (NAS), and 5-methoxytryptamine (5-MT). Melatonin
and its derivatives also stimulated the expression of NRF2 (nuclear factor erythroid 2 [NF-E2]-related
factor 2) and its target enzymes and proteins that play an important role in cell protection from different
damaging factors including UVB. Silencing of NRF2 using siRNA diminished the protective effects
of melatonin, while the membrane melatonin receptors (MT1 or MT2) did not change the activities
of either melatonin or its derivatives. Melatonin and its metabolites enhanced the DNA repair in
melanocytes exposed to UVB and stimulated expression of p53 phosphorylated at Ser-15. In conclusion,
melatonin and its metabolites protect melanocytes from UVB-induced DNA damage and oxidative
stress through activation of NRF2-dependent pathways; these actions are independent of an effect on
the classic membrane melatonin receptors. Thus, melatonin and its derivatives can serve as excellent
protectors of melanocytes against UVB-induced pathology.
Exposure of the skin to ultraviolet radiation (UVR), especially UVB (290–320 nm), absorbed mainly in the epidermis, induces direct DNA damage1 as cyclobutane pyrimidine dimers (CPD) and pyrimidine photoproducts
(6–4)PPs2, 3 with additional production of reactive oxygen species (ROS)4. Collectively, these changes have detrimental effects that include carcinogenesis, cell senescence and other skin pathologies. While nucleotide excision
repair (NER) mechanism is responsible for a repair of photoproducts, removal of ROS or converting them to a
less toxic product depends on enzymes and proteins including: heme-oxygenase, glutathione peroxidase, catalase, gluthatione, etc.5. The enzymes and proteins responsible for antioxidative response are under the control of
nuclear factor erythroid 2 –like 2 (NRF2). In response to oxidative stress and ROS, NRF2 is released from Keap
(Kelch- like ECH-associated protein), translocates to the nucleus, binds to ARE (anti-oxidant response element)
and further activates detoxifying enzymes6.
Due to their constant exposure to oxidative stress caused by different environmental factors, skin cells express
high levels of NRF2 that protects the skin7. NRF2 activation has been a target in treatment of many chronic diseases8. Melanocytes produce melanin that protects the skin from deleterious effects of UV. Studies suggest that
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the susceptibility of melanocytes to oxidative damage is increased due to active melanogenesis9 and increased
levels of ROS10.
Melatonin (N-acetyl-5-methoxytryptamine) protects keratinocytes from detrimental UV radiation11 and a
plethora of other mammalian cells against oxidative stress12–14. Melatonin a is produced primarily in pineal gland
and retina15, but also at extrapineal sites16, including human skin17, 18 and other peripheral organs19. Melatonin,
in addition of modulating circadian rhythms20, also exhibits antioxidant, anti-inflammatory, antiproliferative
and prodifferentiation activities21, 22. Melatonin actions are mediated through its cognate membrane bound type
1 and 2 (MT1 and MT2) receptors or through receptor-independent mechanisms23. Metabolites of melatonin
can also function as potent antioxidants24 or pro-oxidants25. They also act as free radical scavengers or inducers
of anti-oxidative enzymes12, 13, 26. Indolic, kynurenic, and classical pathways are described as the main pathways
of melatonin metabolism12, 17, 27 and can also be produced in skin under UVB exposure28. N-acetylserotonin
(NAS) is produced from serotonin and serves as a melatonin precursor29, 30, but it is also a melatonin metabolite17. N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) is produced from melatonin via kynuric pathway12, 27, through interaction with H2O226, 31, or due to UVB exposure26. Melatonin metabolites also include
6-Hydroxymelatonin (6-OHM) and 5-methoxytryptamine (5-MT) produced via classical or indolic pathway,
respectively11.
Since melatonin can affect the phenotype of normal human melanocytes32, herein we tested whether its
direct or indirect activities include protection of epidermal melanocytes against UVB-induced damage. Potential
receptor-mediated and independent mechanism of action were also evaluated. Since it was proposed that NRF2
acts as a master regulator of antioxidative responses and protection against UV6, we investigated whether protective effects of melatonin and its metabolites in human melanocytes are mediated through activation of NRF2.

Results

Melatonin and its metabolites protect melanocytes from UVB- induces oxidative stress. Skin

cells exposed to UVB produce ROS and suffer DNA damage4. Melatonin can prevent the harmful effects of UVB
on keratinocytes33, as do melatonin metabolites: AFMK, 5-MT, 6-OHM and NAS24. We assessed the protection
from oxidative stress and antioxidative defence mechanisms in cells treated with melatonin or its metabolites
that were irradiated with UVB intensities of 25 or 50 mJ/cm2; this dose does not significantly affect the survival
of melanocytes34. Melatonin protects cells from toxic effects of NO35 or H2O231. To evaluate the protective effects
against oxidative damage, normal human epidermal melanocytes (HEMn) were treated with melatonin or its
metabolites for 24 h. After incubation, cells were exposed to UVB intensities of 0 or 25 mJ/cm2 and NO or H2O2
were recorded 30 min later. Figure 1 shows significant reductions in NO (a) and H2O2 (b) directly produced in
UVB-irradiated cells treated with melatonin or its metabolites; melatonin and its derivatives had similar protective actions. Non-irradiated cells showed no changes in NO or H2O2 when compared to control (Fig. 1a and b),
while the levels of both NO or H2O2, increased in irradiated cells (Fig. 1. inserts a and b). Melatonin, 6-OHM
and 5-MT were the strongest NO reducers, followed by AFMK and NAS. All metabolites showed similar effects
as inhibitors of H2O2. GSH levels are lowered following UVB irradiation36, which was thwarted by melatonin,
as described in human vascular endothelial cells37 and keratinocytes24. Melatonin or its metabolites were added
to the melanocytes before the irradiation. The levels of GSH were recorded 1 h after the cells were exposed to
UVB. As shown in Fig. 1c (insert), a UVB intensity of 25 mJ/cm2 did not significantly reduce the level of GSH
as anticipated, because of the melanogenic activity of melanocytes. Melanin synthesis in melanocytes consumes
cysteine38, which is also an important component of GSH; therefore under the influence of UVB there is an inadequate response in terms of oxidative damage thereby preserving GSH levels in melanocytes9. However, relative
GSH levels rose after treatment with melatonin, AFMK or 6-OHM, while 5-MT and NAS had no effect on GSH
in UVB exposed cells (Fig. 1c).

Melatonin and its metabolites reduce UVB- induced DNA damage in melanocytes.

UVB
induces DNA damage in cells. The DNA repair capacity of melatonin and its metabolites was measured as a
reduction in CPDs in HEMn exposed to UVB. Immediately after irradiation, cells were treated with melatonin
or its derivatives. CPD-positive cells were labelled with CPD-specific antibody and scored under the microscope. As shown in Fig. 2a, UVB irradiation increased production of CPD (Fig. 2, inserted pictures). Treatment
with melatonin or its metabolites caused obvious reduction of CPD levels in cells exposed to UVB 25 mJ/cm2
(Fig. 2c) or 50 mJ/cm2 (Fig. 2d); this contrasted with the lack of such an effect in control cells (Fig. 2b). Melatonin
reduced CPD levels by approximately 40%. While 5-MT and NAS showed a potency similar to melatonin in cells
exposed to 25 mJ/cm2, a slightly weaker effect was noted in cells exposed to 50 mJ/cm2. AFMK and 6-OHM were
somewhat less potent than melatonin, but still effective. To confirm the above findings we used comet assay as
previously described39. Thus, we exposed cells to 200 mJ/cm2 UVB; to measure the protective effects of melatonin
and its metabolites we treated cells with the mentioned compounds 24 h before the exposure to UVB and for an
additional 3 h after. Melatonin, AFMK, 6-OHM, 5-MT and NAS all significantly reduced the tail moment of the
comet images (p < 0.001) in comparison to the non-treated cells (Fig. 2e).
UVB induces tumor suppressor factor p53, as a response to DNA damage40. P53 further accumulates in the
nucleus and activates the DNA repair process41. Melatonin is known to induce phosphorylation of p53 at Ser-1542, 43,
thus activating p53. We tested the ability of melatonin and its metabolites to induce p53 phosphorylation at Ser-15
as a response to UVB damage in comparison to melatonin. Melanocytes were treated for 3 h with melatonin or
its metabolites after UVB exposure. All molecules tested significantly enhanced the expression of Ser-15 phosphorylated p53 (Fig. 3). The intensity of UVB was directly proportional to p53 accumulation (Fig. 3 inserts).
Melatonin enhanced the p53 rise in cells exposed to 25 mJ/cm2 of UVB; p53 more than doubled with melatonin
having the most robust effect of all metabolites, although metabolites were also potent (Fig. 3a). The induction
of p53 under the influence of melatonin, AFMK and 6-OHM was also detected at higher UVB intensity, but to
Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2

2

www.nature.com/scientificreports/

Figure 1. Melatonin, NAS, 6-OHM, AFMK, and 5-MT reduce UVB-induced oxidative stress. UVB-irradiated
(25 mJ/cm2) and non-irradiated melanocytes (comparison presented as inserts) were treated with melatonin
or its metabolites for 24 h prior UV irradiation at the concentration 5 × 10−5 M. NO-(a) or H2O2 (b) produced
in melanocytes were determined 30 min after UVB irradiation, while GSH levels (c) were determined 1 h post
UVB. Data were analyzed using student t-test, *p < 0.05, **p < 0.01.

a lesser extent (Fig. 3b). In contrast, 5-MT and NAS failed to augment the expression of Ser-15 p53 under the
described conditions (Fig. 3b).
To further interrogate the role of melatonin and its metabolites to directly impact nucleotide excision repair
(NER), we utilized a technique termed Oligonucleotide retrieval immunoprecipitation (ORiP)44. The ORiP assay
relies on UV exposure or mock treatment of cells, isolation of nuclear fractions, incubation with a biotinylated
oligonucleotide construct containing a UV-damaged fragment, retrieval of the oligonucleotide by streptavidin
and identification of bound proteins. Nuclear fractions isolated from UV-damaged cells demonstrated binding
of NER complex containing two core factors of this repair pathway: Xeroderma pigmentosum, complementation
Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2
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Figure 2. Melatonin, NAS, 6-OHM, AFMK, and 5-MT exhibit repair capacities in UVB-induced DNA damage
in treated melanocytes as shown by reduced levels of CPD and comet cell tail moments. Cells were treated with
melatonin or its metabolites for 24 h prior UV irradiation at the concentration 5 × 10−5 M, further exposed
to UVB intensities of 25 or 50 mJ/cm2 and immediately treated again with melatonin or its derivatives for 3 h.
Cells were fixed and stained with anti-CPD antibody and further imaged with a fluorescence microscope.
Fluorescence intensity was analysed using ImageJ software and data were analysed using Graph Pad Prizm.
CPD formation under different UVB intensity levels are shown in (a). Figure presents CPD levels after 0 mJ/
cm2 (b), 25 mJ/cm2 (c) and 50 mJ/cm2 (d). Data are presented as percentile of control and were analyzed using
t- test, *p < 0.05, **p < 0.01. As an example, images of the melanocytes stained with CPD antibody (green) and
nuclear staining with propidium iodine (red) show no CPD signal in non-irradiated melanocytes (UV−) and
positive CPD signal in UVB (25 mJ/cm2) irradiated cells (UV+) (magnification 20x). Also, melanocytes were
treated with melatonin or its metabolites before and after UV irradiation (200 mJ/cm3). Tail moment is an index
of DNA damage. Data are analysed using student t-test and p < 0.001 for all conditions (e).

group C (XPC) and Xeroderma pigmentosum, complementation group A (XPA) proteins to photoproduct
containing-substrate (Fig. 4). Further, pre-treatment of either melatonin or one of its metabolites significantly
enhanced the XPC and XPA interactions with the DNA substrate (compared to UV treatment alone; P ≤ 0.05)
with both treatments of 25 mJ/cm2 or 50 mJ/cm2 of UVB (Fig. 4). These results indicate that melatonin and its
metabolites can induce repair of DNA damaged by UVB in HEMn.

Melatonin and melatonin metabolites antioxidative properties are MT receptor independent. Melatonin and its metabolites serve as local antioxidants under oxidative stress conditions caused by

various environmental factors, including UVR11. The exposure to UV promotes the expression of MT1 and MT2
melatonin receptors in skin11, 45, 46. Hence, we evaluated whether melatonin’s protective effects are mediated by
membrane bound melatonin receptors. HEMn were treated with melatonin or its metabolites at different concentrations in the absence or presence of luzindole, a melatonin receptor antagonist47. Melatonin and its metabolites
exerted protective effects against UVB (50 mJ/cm2) induced ROS formation even in the presence of luzindole
(Fig. 5). The effects of melatonin, AFMK and NAS were dose depended, being more pronounced at the higher
Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2
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Figure 3. UVB irradiation intensifies p53 levels. Melatonin, NAS, 6-OHM, AFMK, and 5-MT treated
HEMn elevated levels of p53 phosphorylated at Serine 15 after UVB exposure. Melanocytes were treated with
melatonin or its metabolites for 24 h before UVB exposure. Cells were exposed to UVB intensities of 25 (a),
or 50 mJ/cm2 (b) and immediately treated again with melatonin or its derivatives for 12 h. Cells were further
fixed and stained with anti-phosphorylated p53S15 antibody. Stained cells were imaged with a fluorescence
microscope; fluorescence intensity was analysed using ImageJ software. P53 levels increased proportional to
UVB intensity (insert). Data are analysed using Graph Pad Prizm. Data are presented as percentile of control
and were analyzed using t- test, *p < 0.05, **p < 0.01, ***p < 0.001.
concentration (Fig. 5a and b). Melatonin and AFMK significantly decreased ROS levels at different concentrations, 5 × 10−5 M (p < 0.01) (a) and 1 × 10−6 M (p < 0.05) (b). Other metabolites, 6-OHM and 5-MT showed no
concentration dependency (p < 0.01), while NAS had an effect on ROS only at 5 × 10−5 M. The protective effects
of melatonin and its metabolites at concentrations (5 × 10−5 M or 1 × 10−6 M) were not affected by luzindole
(Fig. 5c and d). To corroborate whether or not the antioxidative effects of melatonin and its metabolites are
membrane bound receptor independent, we tested the levels of both melatonin receptors (MT1 and MT2). The
results showed very low levels of MT receptors in melanocytes. Their detection required immunoprecipitation of
the antigen prior Western blot analysis, which otherwise was negative when whole extracts were probed with the
antibodies (Supplementary Fig. S1).

Melatonin and its metabolites induce the expression of antioxidative enzymes in melanocytes. To further evaluate the status of oxidative stress in UVB irradiated melanocytes we examined the

expression of major antioxidant enzymes, including catalase (CAT), glutathione peroxidase (GPx), glutathione
reductase (GR), glutathione-S-transferase (GSTP1), superoxide dismutase (Cu/Zn-Sod and Mn-SOD), glutamylcysteine synthetase (GCS), and NAD(P)H dehydrogenase, quinine 2 (NQO2) in melanocytes. As shown in
Supplementary Fig. S2, at the RNA level, melatonin and its metabolites induced antioxidant enzymes after cells
were exposed to UVB. The stimulation was dependent on the intensity of UVB; the stronger the intensity of UVB
the greater were the effects of melatonin or its metabolites. The NRF2 transcription factor induces antioxidant
genes; therefore, we have tested the expression of NRF2 and other related genes (HO-1, GCS and GSTP1) relative
to the protective of melatonin or its metabolites in response to UVB induced oxidative stress. Melatonin exhibited
a discernible effect on NRF2 expression. NRF2 levels were 4–5 fold higher in cells treated with melatonin regardless of UVB treatment. All other metabolites were also strong NRF2 inducers (4–6 times when compared to control), while 5-MT was somewhat more potent than the others. As anticipated, HO-1, was also strongly induced
by melatonin or its metabolites after treatment with UVB. Melatonin induced HO-1 levels remarkably 65 times
or 4 times when compared to control after treatment with 75 mJ/cm2 or 50 mJ/cm2, while no effect was observed
after 25 mJ/cm2. Surprisingly, the levels of HO-1 dropped after treatment with melatonin in cells not exposed
to UVB. GCS levels were strongly induced after treatment with melatonin or its metabolites in UVB-irradiated
cells (Supplementary Fig. S2). The levels of GCS ranged from 15–35 times more when compared to control in
cells treated with 75 mJ/cm2 UVB, with melatonin being the most potent. A 3–5-fold increase in GSC levels were
detected after treatment with 50 mJ/cm2 of UVB, with NAS being more potent then melatonin or other metabolites. Similarly, GSTP1 levels were also strongly induced by melatonin and metabolites (Supplementary Fig. S2).
Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2
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Figure 4. Melatonin and its metabolites enhance the XPC- and XPA-DNA-interaction. Melanocytes were
treated with melatonin or its metabolites for 24 h in complete melanocyte medium. Cells were further exposed
to either (a) non UVB-treated (0 mJ/cm2) or (b) 25 mJ/cm2 or (c) 50 mJ/cm2. Synthetic oligonucleotides
(Molecular Beacons) were assembled to form 5′-biotinylated duplex DNA fragment. The substrate provides
a substrate for NER proteins and DNA-protein interactions were determined using anti-XPC and anti-XPA
antibodies as described in the Methods. Treatments significantly different from vehicle were determined by oneway ANOVA; *p ≤ 0.05. All treatments in B or C were statistically significant when compared to vehicle.

Melatonin protective action from oxidative is through NRF2 pathway. To investigate the potential

mechanism of melatonin in protection from oxidative stress caused by UVB in connection to NRF2, we used
NRF2 interfering RNA (NRF2 siRNA) to downregulate NRF2 expression. Figure 6a shows the RT-PCR results
indicating that mRNA level of NRF2 in cells was reduced to more than half in comparison to control. Cells were
also treated with melatonin. Although we have shown that melatonin induces NRF2 (Supplementary Fig. 2),
the silencing of NRF2 abrogated the effects of melatonin, while cells treated with scrambled siRNA showed no
change in NRF2 mRNA (Fig. 6a) or protein levels (Fig. 6 insert). To determine whether antioxidative genes downstream of NRF2-ARE pathway are affected by silencing of NRF2, we examined the HO-1 and NQO2 on mRNA.
Figure 6 shows the reduction of the main phase II detoxifying enzymes: HO-1 (b) and NQO2 (c) in the cells after
silencing NFR2 and treatment with melatonin when compared to scrambled siRNA. Immunofluorescent analysis on melanocytes treated with melatonin or its metabolites after exposure to UVB revealed greater intensity
of NRF2 in comparison to non-irradiated cells (Fig. 7). Melatonin and NAS slightly enhanced NRF2 expression
in non-irradiated cells (Fig. 7a), but all metabolites induced NRF2 after UVB exposure more than double when
compared to control (Fig. 7b), with NAS having the strongest influence. Cells exposed to UVB showed reduction
in NRF2 levels (Fig. 7 insert), which is in accordance with previous reports48.

Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2
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Figure 5. Melatonin, NAS, 6-OHM, AFMK, and 5-MT reduce levels of ROS produced in UVB-irradiated
melanocytes. Cells were treated without (a,b) or with (c,d) luzindole 1 h prior treatment with melatonin,
AFMK, 6-OHT, 5-MT, NAS, or EtOH for 1 h at the concentrations of 5 × 10−5 M (a,c) or 1 × 10−6 M (b,d). CMH2DCFDA dye was added to the cells for 30 min and cells are further irradiated with 50 mJ/cm2 of UVB. ROS
levels in melanocytes were determined 30 min after UVB irradiation. The differences in H2O2 production under
different UVB intensities are shown as insert. Data are presented as percent of control and were analyzed using
t-test, *p < 0.05, **p < 0.01, and ***p < 0.001.

Figure 6. Silencing of the NRF2 in human melanocytes reduced the effect of melatonin on the expression
of NRF2 and NRF2-related genes: HO-1 and NQO2. Melanocytes were transfected with scrambled or NRF2
siRNA and treated with 5 × 10−5 M melatonin. Cells were lysed after treatment and total RNA extracted. NRF2
mRNA (a), HO-1 mRNA (b) and NQO2 (c) levels were measured using reagents for RTPCR and normalized
relative to B-actin RNA. Levels of NRF2 and B-actin were assessed 72 h after transfection with NRF2 or
scrambled siRNA, by western blotting of whole-cell extracts (insert).

Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2
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Figure 7. Melatonin, NAS, 6-OHM, AFMK, and 5-MT treated melanocytes increased NRF2 expression after
UVB exposure. Melanocytes were exposed to UVB intensities of 0 or 50 mJ/cm2 and immediately treated with
melatonin or its derivative for 24 h. Cells were further fixed and stained with anti-NRF2 antibody. Stained cells
were imaged with a fluorescence microscope, fluorescence intensity was analysed using ImageJ software, and
data are analysed using Graph Pad Prizm after 0 mJ/cm2 (a) and 50 mJ/cm2 (b). In addition, UVB diminishes
NRF2 expression (insert). Data are presented as percentile of control and were analyzed using t- test, *p < 0.05,
**p < 0.01.

Discussion

Skin and skin cells are under the constant influence of different environmental stressors, including UVB, which
can induce formation of reactive oxygen species (ROS) and cause oxidative damage4, 49. The damage to the skin
results in cell senescence, photoaging, carcinogenesis, inflammation, etc. Increased levels of ROS after exposure
to UVB has toxic effects on melanocytes, as described in vitiligo50. Natural compounds, such as melatonin, have
the potential of activating endogenous antioxidants defence mechanisms and enhancing protection of skin from
UV12. Melatonin is antioxidant and a free radicals scavenger14; it detoxifies NO35, H2O2 and O2•−31. Studies have
shown the potential beneficial effects of melatonin in treatment of many chronic diseases while it exhibits low or
absent toxicity51. In addition, in animal models, melatonin displays protective effects that are NRF2-mediated52.
Herein, primary human melanocytes were treated with pharmacological doses of melatonin or its derivatives.
We have demonstrated that melatonin, as well as its metabolites (AFMK, 6-OHM, 5-MT, and NAS) protect cells
from UVB-induced oxidative stress, in accordance with previous studies24, 33. The exposure of melanocytes to
UVB resulted in formation of intracellular ROS, including NO and H2O2, as well as the reduction of intracellular glutathione. Pretreatment of melanocytes with melatonin or its metabolites protect against cellular damage
caused by ROS. They all reduced the levels of ROS (Fig. 5), especially NO and H2O2 (Fig. 1). This process does
not involve membrane bound melatonin receptors, since melatonin and its metabolites exhibit their antioxidative
effects even after membrane melatonin receptors were blocked by the receptor antagonist, luzindole (Fig. 5).
Melatonin receptors (MT1 and MT2) are known to be expressed in human epidermal melanocytes at very low
levels (Supplementary Fig. S1). Melatonin also promoted glutathione production, which serves as a first line of
cellular defence against oxidative damage. We have shown that melatonin, AFMK and 6-OH, excluding 5-MT and
NAS, exhibit slight GSH activation (Fig. 1), while stimulating genes encoding GSH production (Supplementary
Fig. S2). Despite the correlation between melanin and ROS levels, the latter accumulate and subsequently reduce
cellular glutathione concentrations in human melanocytes as previously reported9; clearly melatonin plays an
important role in glutathione regulation37, 53.
Oxidative stress can impair the main repair pathway for UVB-induced DNA damage2, 3. Direct UVB-induced
DNA lesions (CPD) were present in melanocytes exposed to UVB (Fig. 2a). CPD formation noticeably decreased
in UVB-irradiated melanocytes treated with melatonin or its metabolites (Fig. 2c,d). Also, melatonin and its
metabolites enhanced UVB-induced DNA repair (Fig. 2e). Tumor suppressor protein p53 is another important
regulator of oxidative stress in skin cells. Activation of p53 is one means of reducing oxidative stress in melanocytes10 resulting from different stressors, including UVB40. Phosphorylation of p53 is important for activation of
Scientific Reports | 7: 1274 | DOI:10.1038/s41598-017-01305-2
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DNA repair in cells54, especially at the Ser-15 site responsible for DNA damage prevention41, which is stimulated
by melatonin23, 55. Melatonin and its metabolites augmented the accumulation of UVB-induced p53 in the nucleus
by increasing phosphorylation of p53 on Ser-15 in melanocytes (Fig. 3), as well as enhanced nucleotide excision
repair via enhanced interactions between damaged DNA and the NER core factors XPC and XPA (Fig. 4), indicating the protective actions of these compounds against UVB induced cell damage, which is in accordance with
previous results24.
We have confirmed (Fig. 7, insert) what has been previously described, i.e., UVB reduced the expression of
NRF2 in melanocytes7, 48. This downregulation was counteracted by treatment with melatonin and its metabolites (Fig. 7a,b). Melatonin has often been described as a regulator of NRF256. Melatonin and its metabolites
also stimulate mRNA expression of antioxidant enzymes and proteins, including catalase, superoxide dismutase, glutathione, NAD(P)H dehydrogenase, glutamylcysteine synthetase and heme oxygenase (Supplementary
Fig. S2). In this study we have demonstrated that melatonin, as well as its metabolites (AFMK, 6-OHM, 5-MT,
and NAS) induce NRF2 downstream genes and proteins which further protect primary human melanocytes from
UVB-induced oxidative stress, similar to their protection in other cells14, 31. The mechanism of this activation is
mediated by upregulation of NRF2 expression and NRF2- dependant pathway (Fig. 7, and Supplementary Figs S2
and S3). When siRNA against NRF2 was used, a downregulation of HO-1 and NQO2 was observed despite the
treatment with the melatonin (Fig. 6). We found that NRF2-activation is important in reduction of UVB-induced
damage to the skin cells, as shown by others57, 58.
Pre-treatment of melanocytes with melatonin or its metabolites conferred protection against UVB mediated ROS damage. Melatonin and its products stimulated NRF2 activation and expression of NRF2 downstream
genes and proteins that counteract oxidative stress. Knocking NRF2 gene confirm the mechanism of melatonin in
NRF2-mediated antioxidative effects on melanocytes. This study demonstrates the benefits of natural products,
i.e., melatonin and its metabolites, in stimulation of NRF2, an endogenous antioxidative pathway, to prevent deleterious effect UVB and UVB-caused oxidative damage. Our data support the protective role of melatonin and it
metabolites in antioxidant skin defence mechanism. The current results demonstrate the high protection that melatonin and its metabolites, as natural antioxidants, can provide to skin cells against UVB-induced damage. While
there are differences in the potencies of the protection provided by melatonin and its metabolites, these differences
are not great given that all melatonin metabolites exhibited strong protective effects against UVB-induced oxidative
damage to melanocytes. The present study identifies local melatoninergic system as the protector of melanocytes
against UVB-induced pathology, effects that can be amplified by topical application of melatonin or its derivatives.

Material and Methods
Chemicals.

The source of chemicals is described previously24. All chemicals were diluted in pure ethanol. AFMK (N 1-acetyl-N 2-formyl-5-methoxykynuramine) (10005254) was purchased from Cayman
Chemical Company (Ann Arbor, MI, USA) (catalog number 10005254), while others were purchased from
Sigma-Aldrich (St. Louis, MO): Melatonin (N-acetyl-5-methoxytryptamine) (M5250), 6-hydroxymelatonin (3-(N-acetylaminoethyl)-6-hydroxy-5-methoxyindole) (H0627), N-acetylserotonin (N-acetyl-5hydroxytryptamine) (A1824), 5-methoxytryptamine (2-(5-methoxy-1H-indol-3-yl)ethanamine) (286583).

Human tissue samples.

The experiments were performed in accordance with relevant guidelines (see
below) and the experiments were approved by the Institutional Review Board (IRB) at the University of Alabama
Birmingham. This protocol was identified as not subject to FDA regulation and not Human Subject Research (IRB
protocol N150915001 – Endocrine Functions of the Skin – revised version). Where necessary it is also covered by
an exempt protocol category #4 for use of the archival or stored material approved on 7/2/2015 under IRB registration # IRB00000726 under the title “Neuroendocrinology of the skin and other peripheral organs” E150427002.
No human subjects were involved in this protocol. However, primary melanocytes were cultured from foreskin
that would normally be discarded during surgery. Animal subjects were not included in experimental design.

Cell culture.

Human epidermal melanocytes (HEMn) are isolated from neonatal foreskin of
African-American donors and cultured for experiments as previously described59. Cells were grown in melanocyte growth media (MGM) supplemented with melanocyte growth factors (MGF) (Lonza Walkersville Inc,
Walkersville, MD). For the experiments with UVB the media were replaced with phosphate buffered saline (PBS)
prior the exposure. Cells in their third passage were used for the experiments and pretreated with melatonin or its
derivatives 24 h before exposure to UVB after UVB exposure for indicated amount of time. It must be noted that
melanocytes used for the experiments were darkly pigmented with dendritic morphology that was not affected
by UVB doses of 25 and 50 mJ/cm2 during relatively short periods of incubation including 3 and 24 h after UVR
treatment (Supplemental Fig. S3). UV transilluminator 2000 from Bio-RAD Laboratories was used for UVB irradiation following protocols and UV spectra reported previously39.

Comet assay. DNA damage and repair were assessed using Comet assay, and detecting levels of CPD dimers

and p53. The comet assay was performed following the manufacturer’s protocol (Trevigen, Gaithersburg, MD)
with experimental design as previously described39. Melanocytes were seeded in 12-well plates. Cells were treated
with melatonin or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for
24 h. Then, the medium was replaced with 1 × PBS and cells were exposed to UVB 200 mJ/cm2. PBS was removed
and replaced with fresh medium containing compounds and cells were further incubated for 3 h at 37 °C. After
detaching, cells were counted and used for the comet assay. Cell suspensions at a density of 1 × 105/ml were combined with molten 1.2% low-melting-point agarose, diluted 1:10, placed onto two frosted slides precoated with
0.6% normal agarose, and incubated at 4 °C for 30 min. Cells were further digested in lysis solution at 4 °C for
60 minutes. DNA strand breaks were separated by electrophoresis in alkaline electrophoreses solution (200 mM
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NaOH, 1 mM EDTA, pH > 13) in horizontal gel electrophoresis slide tray (Comet-10, Thistle Scientific, UK).
DNA breaks were exposed to alkaline unwinding for 40 min at room temperature after which electrophoresis was
performed at 25 V for 50 min. Following neutralization in neutralizing buffer (0.4 M Tris, pH7), comets were visualized by propidium iodide (Sigma-Aldrich, St. Louis, MO) staining. The slides were examined and images were
captured using Nikon fluorescent microscope and the Leica digital DM 4000b fluorescent microscope equipped
with image analysis software. Approximately 60 comet images were taken for each condition. DNA damage was
measured by the tail length using Comet Score software available from http://www.scorecomets.com.

CPD dimers. Following the manufacturer protocol, cells were stained with anti-CPD antibody and nuclei
were stained red with propidium iodide as previously described24. CPDs in cultured normal melanocytes were
visualised using immunofluorescence. Briefly, HEMn were plated onto chamber slides, treated with melatonin
or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for 24 h prior UVB
exposure, and further for 3 h after the exposure. Following the manufacturer protocol, cells were stained with
anti-CPD (clone TDM2) (Cosmo Bio Co Ltd., Tokyo, Japan) (dil 1:100) and subsequently with goat anti-mouse
IgG-FITC (Santa Cruz Biotechnology, Santa Cruz, CA) (1:100). Nuclei were stained red with Vectashield mounting media with propidium iodide (Vector Laboratories, Burlingame, CA). Stained cells were imaged with a fluorescence microscope. Pictures recorded were analysed using ImageJ software (NIH free download).
NRF2 in cultured normal melanocytes was visualised using immunofluorescence. Briefly, HEMn were plated onto
chamber slides, treated with melatonin or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for 24 h after UVB exposure. Following the manufacturer protocol, cells were stained with anti-NRF2
(C20) (sc-722, Santa Cruz Biotech., Santa Cruz, CA) (dil 1:50) and subsequently with Alexa-Fluor 488 goat anti
rabbit IgG (Invitrogen Molecular Probes, Eugene, Oregon, USA) (1:100). Nuclei were stained red with Vectashield
mounting media with propidium iodide (Vector Laboratories, Burlingame, CA). Stained cells were imaged with a
fluorescence microscope. Pictures recorded were analysed using ImageJ software (NIH free download).
Immunofluorescence for p53. Melanocytes were plated onto chamber slides in duplicates. Cells were
treated with melatonin, or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000)
for 24 h prior UVB exposure and for 3 h for detection of phosphorylated p53 at Ser-1555. Cells were further fixed
in 4% paraformaldehyde (PFA) for 10 min at room temperature and washed three times with 0.1% Triton X-100
(BioRad, Hercules, CA) in PBS to permebealize membrane. Blocking was performed in 10% FBS in PBS for 1 h
at RT after quenching of endogenous peroxidase with 1% H2O2 (BioRad, Hercules, CA) in PBS. Cells were incubated in phospho p53 Ser-15 (9284 Cell Signaling, Danvers, MA) primary antibodies diluted in blocker 1:100
overnight at 4 °C. The following day cells were washed and incubated with secondary antibody Alexa-Fluor 488
goat anti-rabbit IgG (Invitrogen Molecular Probes, Eugene, Oregon, USA) diluted in blocker 1:100 for 1 h at RT.
After washing with PBS, nuclei were stained red with Vectashield mounting media with propidium iodide (Vector
Laboratories, Burlingame, CA). Stained cells were imaged with a fluorescence microscope. Pictures recorded were
analysed using ImageJ software (NIH free download).
Reactive oxygen species (ROS) assays.

Reactive oxygen species (ROS) assays were used to measure
ROS levels in HEMn using a fluorescence method as previously described24. Luzindole is used in accordance
with the literature47. Melanocytes were plated onto 96-well plate. The following day, medium was removed and
fresh luzindole (Sigma-Aldrich (St. Louis, MO) was added to the cells at the concentration of 50 µM for 1 h. Cells
are further treated with melatonin or its metabolites at the concentrations of 5 × 10−5 M, 1 × 10−6 M, 1 × 10−8 M,
1 × 10−10 M, or ethanol (vehicle, dilution 5:1,000) for 1 h. After incubation, cells were washed with cold 1×PBS.
CM-H2DCFDA dye (Molecular Probes, Invitrogene, Eugene, Oregon) diluted in HEPES at the 5 µM concentration was added and cells were incubated for additional 30 min. After preincubation with CM-H2DCFDA dye,
cells were irradiated with 50 mJ/cm2 of UVB and placed in incubator. Thirty minutes post-UVB exposure, cells
were washed with PBS. The generation of ROS was determined by measuring the fluorescence at 480 nm excitation and 528 nm emission, on SpectraMax M2e instrument (Molecular Devices, Sunnyvale, CA). Data were presented as percentile of control (EtOH- treated cells).

Oligonucleotide retrieval immunoprecipitation (ORiP).

The XPC- and XPA-DNA-interaction was
tested using oligonucleotide retrieval immunoprecipitation (ORiP) as previously described44. HEMn were treated
with melatonin or its metabolites for 24 h in complete melanocyte medium and 2% chFBS. Cells were further
exposed to either 25 mJ/cm2 or 50 mJ/cm2 or non UVB-treated (0 mJ/cm2). After UVB treatment, cells were incubated in fresh medium supplemented with melatonin or its metabolites for an additional 1 or 3 h, before they
were harvested by scraping and pelleted. Soluble nuclear extract was obtained as previously described44. Synthetic
oligonucleotides (Molecular Beacons) were assembled to form 5′-biotinylated duplex DNA fragment that provide a substrate for NER proteins. A 30-nt oligonucleotide, 5′-CTCGTCAGCATCTTCATCATACAGTCAGTG
-3′, was exposed to 10 J/m2 of UVC, annealed and ligated with two oligonucleotides as previously described44.
After indicated treatments, soluble nuclear extracts (50 µg) were incubated with the biotinylated oligonucleotide
in streptavidin-coated 96 well plates (Thermo-Scientific) (0.01 nM per well) for 10 minutes at 30 °C. Wells were
washed with 40 mM Tris-HCl (pH 7.5) containing 0.01% BSA (wash buffer) followed by fixation in 4% paraformaldehyde. After three washes, 2 µg of either anti-XPA or anti-XPC was added for 1 h at room temperature.
Detection was accomplished using an HRP-conjugated anti-rabbit secondary antibody (Abcam) for 1 h followed
by the addition of 1-Step Ultra TMB ELISA Substrate (Pierce) to each well and absorbance measured at 400 nm.

Nitric oxide (NO −) assays.

Nitrite levels (NO −) levels were measured using Griess reagent (1%
sulfanilamide-0.1% N-1-naphthyl-ethylenediamine dihydrochloride in 2.5% phosphoric acid) (Sigma, St. Louis,
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MO) as previously described60. Melanocytes were seeded onto 60 mm culture plates. Cells were treated with melatonin or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for 24 h. After
incubation, cells in cold 1×PBS were irradiated with the UVB intensity of 0 or 25 mJ/cm2. After 30 min of incubation at 37 °C cells were harvested by scraping. Cell pellets were further centrifuged at 3000 g for 5 min, supernatant was collected and mixed with an equal amount of Griess reagent. The generation of NO was determined by
measuring the absorbance at 540 nm in a spectrophotometer of purple azo compound formed from the reaction
between nitrates formed in samples and Griess reagent. Data were presented as concentration of nitite (µmol) per
protein amount (mg), and further as percentile of control (EtOH- treated cells).

H2O2 assays. Hydrogen peroxide (H2O2) levels were measured using a luminescence method61. Melanocytes
were treated with melatonin, its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5: 1,000)
for 24 h. After incubation, cells in 1×PBS were irradiated with the UVB intensity 0 or 25 mJ/cm2. The generation of
H2O2 was determined by measuring the luminescence of luminol (Sigma, St. Louis, MO) by H2O2 that is released by
melanocytes 30 min after UV exposure. Aliquots from each dish were mixed with lumiol and horse radish peroxidase
(Sigma, St. Louis, MO) in respiratory buffer and luminescence was measured in a Turner Luminometer (TD20/20)
(Promega, Madison, WI). The specificity of the reaction was determined by treating separate UV-irradiated cells
with 300 units/mL of catalase (Sigma, St. Louis, MO), which degraded H2O2 to H2O and O2. Data were presented as
concentration of H2O2 (pmol) per 0.1 million cells and further as percentile of control (EtOH treated cells).
Glutathione (GSH) assay.

Glutathione (GSH) levels were measured using a fluorometric method60.
Melanocytes were treated with melatonin, or its metabolites at the concentration of 5 × 10−5 M, or ethanol
(vehicle, dilution 5:1,000) for 24 h. After incubation, cells were irradiated with the UVB intensity of 0 or 25 mJ/
cm2. After UV exposure cells were further incubated for 1 h at 37 °C. Cells were harvested with trypsinization and washed with 1×PBS-EDTA, pH8. After centrifugation, cell pellets were resuspended in ice cold 5%
meta-phosphoric acid (MPA) (Sigma, St. Louis, MO), sonicated, and centrifuged at 12,000 rpm for 5 min. After
collection of supernatant, aliquots were taken for protein determination. Supernatant was further mixed with
1×PBS-EDTA buffer and OPAME (o-phthaldialdehyde (Sigma, St. Louis, MO) in methanol (Fisher, Pittsburgh,
PA) and borate buffer (potassium-tetraborate, Sigma, St Lois, MO). Mixtures were further aliquoted in 96-well
plate, incubated for 15 min at RT and GSH levels were determined by measuring the fluorescent signal at 350 nm
excitation and 420 nm emission, on SpectraMax M2e instrument (Molecular Devices, Sunnyvale, CA). Data were
presented as percentile of control (EtOH- treated cells).

Reverse transcription polymerase chain reaction (RT-PCR). HEKn cells were cultured for three days

in 60 mm petri dishes (MidSci, St. Louis, MO). Cells were treated with melatonin, or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5: 1,000) for 24 h before UVB exposure and for additional
3 h post UVB exposure. Cells were exposed to different intensity UVB including: 0, 25, 50 or 75 mJ/cm2. After
UV exposure cells were further incubated for 1 h at 37 °C. RNA from cells was extracted using Absolutely RNA
RT–PCR Miniprep kit (Stratagene, La Jolla, CA) as previously described62. Reverse transcription reaction was
performed using High Capacity cDNA reverse transcription Kit (Applied Biosystems, Foster City, CA). The reaction was performed with LightCycler 480 Probes Master (Roche Applied Science, Indianapolis, IN). The sequence
and source of primers are shown in Table 1 in supplementary file. Real-time PCR was performed using Kapa
SYBR Fast qPCR Master Mix (Kapa Biosystems, Boston, MA) performing 35 cycles (95 °C for 15 seconds, 60 °C
for 30 sec, 72 °C 10 sec) in triplicates. Data was collected with a Roche Light Cycler 480, and the amount of mRNA
was normalized by comparative Ct method, using B-actin as a housekeeping gene.

siRNA transfection. Melanocytes were transfected with 50 nM NRF2 or scrambled siRNA (Santa Cruz Inc,
Santa Cruz, CA) using lipofectamine plus (Invitrogen, Eugene, Oregon). Twenty-four hours after transfection,
cells were treated for an additional 48 h with 5 × 10−5 M melatonin. RNA was isolated and used for gene expression analysis and, also, whole cell extracts were prepared for protein analysis.
Immunoprecipitation analysis. HEKn cells were lysed in RIPA buffer (Cell Signaling, Beverly, MA, USA)
on ice for 1 h. After centrifugation (15, 339 g for 20 min at 4 °C), the lysates were incubated with 25 μl of Protein
A/G PLUS-Agarose beads (Santa Cruz Inc., Santa Cruz, CA) and 1 μg of normal goat serum for 3 h with shaking at
4 °C, pelleted by centrifugation for 10 min at 4 °C, and incubated overnight at 4 °C on a rocking platform with 25 μl
of Protein A/G PLUS-Agarose beads and 2 μg of anti MEL1A (sc13186), anti-MEL1A (sc13179), anti-MEL1B
(sc13177), or anti-MEL1B (sc28453) antibodies (Santa Cruz Inc., Santa Cruz, CA). Immunoprecipitates were collected by centrifugation, washed four times with RIPA buffer, separated by SDS–PAGE, and subjected to immunoblotting, as described previously62. The primary antibodies used for immunoblotting were goat polyclonal
antibodies against MEL1A or MEL1B. The secondary antibody used was HRP anti-goat IgG.
Experiments were repeated three times and analysed using Student’s t-test or anova (*) and appropriate post
hoc test, using Microsoft Excel and Prism 4.00 (GraphPad Prism 4 Software) and representative graphs have been
prepared. Statistically significant differences are denoted in the figures and corresponding figure legends.
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